CN103249415B - 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 - Google Patents
包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 Download PDFInfo
- Publication number
- CN103249415B CN103249415B CN201180058951.9A CN201180058951A CN103249415B CN 103249415 B CN103249415 B CN 103249415B CN 201180058951 A CN201180058951 A CN 201180058951A CN 103249415 B CN103249415 B CN 103249415B
- Authority
- CN
- China
- Prior art keywords
- valsartan
- lercanidipine hydrochloride
- lercanidipine
- tablet
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100125804 | 2010-12-09 | ||
KR10-2010-0125804 | 2010-12-09 | ||
PCT/KR2011/009413 WO2012077968A2 (en) | 2010-12-09 | 2011-12-07 | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103249415A CN103249415A (zh) | 2013-08-14 |
CN103249415B true CN103249415B (zh) | 2017-12-12 |
Family
ID=46207595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180058951.9A Active CN103249415B (zh) | 2010-12-09 | 2011-12-07 | 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2648730A4 (es) |
KR (1) | KR101414814B1 (es) |
CN (1) | CN103249415B (es) |
AR (1) | AR084195A1 (es) |
AU (1) | AU2011339150B2 (es) |
BR (1) | BR112013013415A2 (es) |
CL (1) | CL2013001626A1 (es) |
CO (1) | CO6721030A2 (es) |
DO (1) | DOP2013000115A (es) |
EA (1) | EA201390844A1 (es) |
IL (1) | IL226449A0 (es) |
MX (1) | MX2013005716A (es) |
PE (1) | PE20140699A1 (es) |
SG (1) | SG190326A1 (es) |
UA (1) | UA108277C2 (es) |
UY (1) | UY33772A (es) |
WO (1) | WO2012077968A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755322B (zh) * | 2012-07-24 | 2013-12-11 | 兆科药业(广州)有限公司 | 一种乐卡地平和阿托伐他汀复方制剂 |
US20160045497A1 (en) * | 2013-03-12 | 2016-02-18 | Lg Life Sciences Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
KR102233986B1 (ko) * | 2019-06-25 | 2021-03-30 | 경남과학기술대학교 산학협력단 | 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
EP1694305B1 (en) * | 2003-12-01 | 2019-10-16 | Recordati Ireland Limited | Pharmaceutical compositions comprising lercanidipine |
WO2007001067A2 (en) | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
-
2011
- 2011-12-06 UY UY0001033772A patent/UY33772A/es not_active Application Discontinuation
- 2011-12-07 AR ARP110104583A patent/AR084195A1/es unknown
- 2011-12-07 BR BR112013013415A patent/BR112013013415A2/pt not_active IP Right Cessation
- 2011-12-07 MX MX2013005716A patent/MX2013005716A/es unknown
- 2011-12-07 EA EA201390844A patent/EA201390844A1/ru unknown
- 2011-12-07 CN CN201180058951.9A patent/CN103249415B/zh active Active
- 2011-12-07 UA UAA201307936A patent/UA108277C2/ru unknown
- 2011-12-07 WO PCT/KR2011/009413 patent/WO2012077968A2/en active Application Filing
- 2011-12-07 AU AU2011339150A patent/AU2011339150B2/en not_active Ceased
- 2011-12-07 SG SG2013038211A patent/SG190326A1/en unknown
- 2011-12-07 KR KR1020110130400A patent/KR101414814B1/ko active IP Right Grant
- 2011-12-07 PE PE2013001346A patent/PE20140699A1/es not_active Application Discontinuation
- 2011-12-07 EP EP11847739.7A patent/EP2648730A4/en not_active Withdrawn
-
2013
- 2013-05-20 IL IL226449A patent/IL226449A0/en unknown
- 2013-05-21 DO DO2013000115A patent/DOP2013000115A/es unknown
- 2013-06-06 CL CL2013001626A patent/CL2013001626A1/es unknown
- 2013-06-21 CO CO13147794A patent/CO6721030A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120089787A (ko) | 2012-08-13 |
MX2013005716A (es) | 2013-06-12 |
UA108277C2 (ru) | 2015-04-10 |
AU2011339150B2 (en) | 2015-09-10 |
DOP2013000115A (es) | 2014-07-31 |
BR112013013415A2 (pt) | 2019-09-24 |
EP2648730A4 (en) | 2014-08-06 |
UY33772A (es) | 2012-07-31 |
PE20140699A1 (es) | 2014-06-13 |
EA201390844A1 (ru) | 2013-11-29 |
SG190326A1 (en) | 2013-06-28 |
EP2648730A2 (en) | 2013-10-16 |
IL226449A0 (en) | 2013-07-31 |
CO6721030A2 (es) | 2013-07-31 |
WO2012077968A2 (en) | 2012-06-14 |
CL2013001626A1 (es) | 2013-10-04 |
KR101414814B1 (ko) | 2014-07-21 |
CN103249415A (zh) | 2013-08-14 |
AU2011339150A1 (en) | 2013-06-06 |
WO2012077968A3 (en) | 2012-07-26 |
AR084195A1 (es) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5597343B2 (ja) | 抗痴呆薬を含有する組成物 | |
US7741374B1 (en) | Methods of use of fenofibric acid | |
US20100047341A1 (en) | Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory | |
US20060246003A1 (en) | Composition containing anti-dementia drug | |
KR101205633B1 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
JPH11505542A (ja) | 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤 | |
CN103751193A (zh) | 包含利拉列汀和任选的sglt2抑制剂的药物组合物及其用途 | |
KR20070085754A (ko) | 안정화된 라미프릴 조성물 및 제조 방법 | |
WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
KR101515490B1 (ko) | 고혈압 및 대사증후군 질환 치료용 약학적 조성물 및 이의 용도 | |
CN108156807A (zh) | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 | |
JP2011507973A (ja) | アムロジピンとバルサルタンとの医薬組成物 | |
US20030147957A1 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
CN103249415B (zh) | 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法 | |
CN101653440B (zh) | 含有氨氯地平系列盐和普利类药物的治疗组合物 | |
CN106310278A (zh) | 一种含叶酸的多联降压药物组合物 | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
CN101416966B (zh) | 一种治疗高血压的药物组合物 | |
CN102784143B (zh) | 一种含美托洛尔和非洛地平的单层渗透泵控释制剂 | |
EP4079297A1 (en) | Pharmaceutical formulation comprising cibenzoline or salt thereof | |
TWI827828B (zh) | 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑 | |
US10154963B2 (en) | Controlled-release formulations comprising Torsemide | |
EP3087978A1 (en) | Sustained-release pharmaceutical composition containing acebrophylline and hydrophillic sustained-release agent | |
WO2024047208A1 (en) | Anticoagulant therapy with an improved dosage regimen | |
KR20240045205A (ko) | 메타돈과 그 이성질체, 에스메타돈 및 레보메타돈과 유도체의 변형 방출 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170913 Address after: Seoul, South Kerean Applicant after: LG Chemical Co., Ltd. Address before: Seoul, South Kerean Applicant before: LG Life Sciences Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant |